The body typically produces sufficient L-carnitine for everyday metabolic needs, and additional amounts can be obtained through dietary sources, particularly red meat, poultry, fish, and dairy products
Targeted therapies present significant advantages in the treatment of AR, particularly in the regulation of the Th17/Treg immune balance, as summarized in Table 4
Kalscheuer R, Stveken T, Malkus U, Reichelt R, Golyshin PN, Sabirova JS, Ferrer M, Timmis KN, Steinbchel A
332 NASH, now termed metabolic dysfunction-associated fatty hepatitis (MASH), is characterized by hepatic steatosis, inflammation, hepatocellular injury, and varying degrees of fibrosis and is linked to lipid metabolism disorders